The study failed to achieve its primary (changes in quantitative muscle MRI) and secondary endpoints (histology parameters, MR spectroscopy, and functional evaluations) except for a positive trend in muscle MRI fat fraction in the thigh, which remained stable in the givinostat group but increased in the placebo group [ 31 ▪ ].
1
—
—